Business Context and Reporting Period
This Form 8-K is a current report filed by Sonus Pharmaceuticals, Inc. on April 21, 2004. The filing serves to announce the company's financial results for the fiscal quarter ended March 31, 2004. The report incorporates a press release (Exhibit 99.1) by reference but explicitly states that the press release is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text provided does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the referenced press release (Exhibit 99.1), which is not included in the input text. Consequently, no financial metrics can be extracted from this document alone.
Material Changes
The filing does not provide specific details on material changes versus the prior comparable period. It only confirms the issuance of results for the quarter ended March 31, 2004.
Guidance, Outlook, and Risks
The text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The document functions solely as a notification of the press release's existence.
Investor Verification Checklist
- Verify the specific financial results (revenue, net loss, cash position) by reviewing the attached Exhibit 99.1 Press Release, as the 8-K text itself contains no numbers.
- Confirm the company's operational status and cash runway based on the Q1 2004 results referenced in the press release.
- Note that the press release is not legally "filed" for Section 18 liability purposes, which may affect the weight of any forward-looking statements contained therein.